ETOL-Elderly Study of the Efficiency of the Innovative Food Supplement in Elderly Adults

Vitamin d Deficiency Clinical Trial

— ETOL-Elderly  

Official title:

Study of the Efficiency of the Innovative Food Supplement in Improving Nutritional Status of Elderly Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05661006
• Other study ID #: 2020/1-ET-SK
• Status: Completed
• Phase: N/A
• Start date: February 20, 2020
• Est. completion date: June 29, 2020

Study information

• Verified date: June 2023
• Source: Nutrition Institute, Slovenia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this pilot study is to conduct a study on geriatric population in Slovenia (non-users of dietary supplements/medicines with vitamine D, vitamin B12 and protein) and assess deficiency of selected nutrients, and to investigate the efficiency of the innovative food supplement prototype in improving nutritional status of elderly adults.

Description:

The main objective is to show that in the geriatric population regular use of investigation food supplement would improve nutritional status. The study should provide answers to the following main questions: (1) Is regular use of investigated product beneficial for improving serum vitamin D levels in elderly population? (2) Is regular use of investigated product beneficial for increasing daily protein intake in elderly population? (3) Is regular use of investigated product beneficial for improving vitamin B12 status in elderly population?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 29, 2020
• Est. primary completion date: May 5, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years to 95 Years

Eligibility

Inclusion criteria:

• Subject Informed consent form (ICF) is singed
• Aged at least 65 at the time of the signature of ICF
• A body mass index lower than 32 kg/m2
• Willing to avoid a consumption supplementation with protein, vitamin D and vitamin B12 during the study
• Willing to follow all study procedures, including attending all site visits (including blood sampling) and keeping a diary for using the product and six 24-hour dietary records (3x pre-intervention, 3x during last week of the intervention)

Exclusion criteria:

• Medical treatment with Vitamin D and/or Vitamin B12
• Supplementation with protein, vitamin D and/or vitamin B12 during least 2 months
• Known drug and/or alcohol abuse
• Known lactose/gluten intolerances/food allergies
• Inadequate veins (in the opinion of the investigator) or known contraindication for venous blood withdrawal
• Have chronic bowel disease (ulcerative colitis, Chron's disease, stomach or duodenal ulcer, chronic inflammation of the stomach or duodenum)
• Have acute gastrointestinal infection with vomiting and / or diarrhea
• Have planned general anaesthesia or colonoscopy at the time of the study
• Have malabsorption syndrome
• Less than 5 years after treatment for gastrointestinal cancer (stomach, duodenum or colon)
• Have stomach or bowel resection
• Do not have neat and functional teeth
• Take regular or occasional laxative products
• Use antacids (Rupurut / Rutacid / Talcit)
• Mental incapacity that precludes adequate understanding or cooperation
• Participation in another investigational study

Related Conditions & MeSH terms

• Protein Deficiency
• Vitamin B 12 Deficiency
• Vitamin d Deficiency

Intervention

Dietary Supplement:
• Use of food supplement
On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end of the intervention. Subjects are recording daily consumption of the product. Intervention diet recording during last week of intervention (days 49-56): 3x24h dietary records (two days during weekday, one weekend day). Intervention end on day 56 ±3 (fasted condition): Measuring S-25-OH-VitD, S-VitB12, S-protein, S-albumin, S-CRP Measuring body weight & height Collecting data regarding the palatability of the product
• Use of placebo food supplement
On day 1 subjects start with intervention on prearranged day. First dosage of test product is consumed during day 1 between regular meals (not as meal substitute). In the following days: continuation of consumption of test product once per day until end

Locations

Country	Name	City	State
Slovenia	VIZERA	Trzin

Sponsors (4)

Lead Sponsor	Collaborator
Nutrition Institute, Slovenia	European Regional Development Fund, Frutarom Etol d.o.o., Vizera d.o.o.

Country where clinical trial is conducted

Slovenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in serum vitamin D levels will be determined	Serum level of 25-OH-vitamin D will be measured before and after the intervention for each individual.	56 days
Secondary	Change in dietary protein intake will be determined	Dietary protein intake will be estimated before and after the intervention for each individual, using 3x24h food records.	56 days
Secondary	Change in serum vitamin B12 levels will be determined	Serum level of vitamin B12 will be measured before and after the intervention for each individual.	56 days
Secondary	Malnutrition at baseline	Risks for malnutritition at baseline will be assessed using dietary records (3x24h food record: energy, protein and plasma concentration of 25-OH-D and vitamin B12.	baseline